Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | - | - |
INDMoney rank | 7/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 6 Years | ||
Fund Size | 8081 Cr | 4915 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.91% | 1.18% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 45 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.43%) Divi's Laboratories Ltd (9.28%) Lupin Ltd (7.27%) Cipla Ltd (5.71%) Apollo Hospitals Enterprise Ltd (5.31%) | Sun Pharmaceuticals Industries Ltd (13.5%) Dr Reddy's Laboratories Ltd (8.95%) Cipla Ltd (8.85%) Divi's Laboratories Ltd (6.71%) Aurobindo Pharma Ltd (5.3%) | ||
No of Sectors | 1 | 3 | ||
Top 3 Sectors | Health (100%) | Health (90.94%) Basic Materials (6.08%) Financial Services (2.97%) | ||
Equity % | 99.46% | 98.28% | ||
Debt % | - | - | ||
P/E | 35.57 | 28.98 | ||
P/B | 5.87 | 4.16 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 3.89% | 3.78% | ||
3-Month Return | 7.52% | 4.64% | ||
6-Month Return | -1.67% | -1.46% | ||
1-Year Return | 17.52% | 23% | ||
3-Year Return | 21.24% | 25.34% | ||
5-Year Return | 23.82% | 26.3% |
Sharpe | 0.81 | 1 | ||
Alpha | 0.5 | 3.61 | ||
Beta | 0.9 | 0.93 | ||
Standard Deviation | 15.85 | 16.26 | ||
Information Ratio | -0.21 | 1.05 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Dharmesh Kakkad |